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Introduction: Most collectively funded healthcare systems set limits to their benefit package. Doing so re- 
quires judgements which may involve economic evaluations. Performing such evaluations brings method- 
ological challenges, which may be more pronounced in non-pharmaceutical interventions. For example, 
for medical devices, the validity of assessment results may be limited by learning effects, incremental 
innovation of the devices and the context-dependency of their outcomes. 
Objective: To review the extent to which "learning effects", "incremental innovation" (related to out- 
comes) and "context-dependency" are included and/or discussed in peer reviewed economic evaluations 
on medical devices using Transcatheter Aortic Valve Implementation (TAVI) as an example. 
Methods: A systematic review was performed including full economic evaluations of TAVI for operable 
patients with aortic stenosis identified using the Pubmed database. Study characteristics, study results 
and text fragments concerning the aforementioned aspects were extracted. The quality of the studies 
was assessed using a quality checklist (CHEC-extended). 
Results: Within 207 screened records, 15 studies were identified. Two studies referred to all three aspects, 
four studies referred to none. "Learning effects" were discussed in five studies, one of which described a 
method to cope with this challenge. “Incremental innovation” was described in seven studies. Limitations 
in generalizability of results related to context of care provision were discussed in seven studies. 
Conclusion: The challenges related to economic evaluations of TAVI and their influence on the validity of 
reported results, are typically only partly discussed and rarely dealt within peer reviewed studies. It is 
important for better informed policy decisions that this improves. 
© 2020 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. 


























Collectively funded healthcare systems in Western countries set
imits to their benefit package. Setting these limits requires desig-
ated authorities to make judgements on whether specific health-
are interventions merit a claim on collective means. These pol-
cy judgements may be based on the assessment and appraisal of
ultiple aspects of health technologies, for instance on effective-
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and context dependency? A review, Health Policy and Technology, httpmong these considered aspects. This aspect can be assessed us-
ng an economic evaluation. A growing number of these economic
valuations are conducted: i.e. until 2009 almost 2,500 cost-utility
nalyses (a specific form of economic evaluation) were published
n English [2] , in 2017 this number had grown to more than 7,0 0 0
3] . Guidelines on how to perform economic evaluations in health-
are are available for many jurisdictions [e.g. 4 ]. However, despite
he growing number of published evaluations, and the existence
f guidelines, performing economic evaluations is still not with-
ut methodological challenges. As a result, estimates of interven-
ions’ incremental cost-effectiveness ratios (ICERs) may be inaccu-
ate and thus policy makers may be misinformed. While some of
he methodological challenges in performing economic evaluations
re relevant to all types of healthcare, others are more pronounced
n specific types of interventions. For medical devices three of such
pecific challenges have been repeatedly identified as important:an open access article under the CC BY license 
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learning effects, incremental innovation and context-dependency
of outcomes [5–9] . Although more specific challenges may exist,
these three thus seem particularly relevant in the context of med-
ical devices. The concept of learning effects, or learning curves,
refers to the situation in which the (cost-)effectiveness of an inter-
vention is related to the experience (and resulting competence) of
care providers with using a particular procedure or device. Learn-
ing effects can be relevant when accumulating experience and
knowledge of care providers, e.g. during a period of proctoring,
lead to an increase in the average effectiveness and/or a decrease
in the average costs. Incremental innovation refers to incremental
changes through time of the medical device itself (e.g. alterations
of its technical specifications) or its provision/use (e.g. alterations
in the surrounding clinical pathway), which may cause changes
in the efficacy and/or costs of the intervention as well. Finally,
context-dependence of outcomes refers to a dependency of (cost-
)effectiveness on the (organisational) context of care provision (e.g.
organisational size or academic versus non-academic hospitals). All
three aspects may thus influence the observed cost-effectiveness,
leading to questions of whether this observed cost-effectiveness is
generalisable in time, context and place, and therefore most rele-
vant in informing a policy decision (which of course also depends
on the policy problem that needs to be addressed). Flexible mod-
elling and appropriate data collection may be among possible solu-
tions to cope with these challenges [10] . Alternatively, researchers
may provide a discussion of (the relevance of) these challenges
to, at least, inform policy makers on limitations of their study, or
present specific sensitivity analyses. Otherwise, when these aspects
are (potentially) relevant yet ignored when conducting and report-
ing an economic evaluation, the reported results may misinform
policy makers, who may not be aware of these specific challenges
and their impact on the results. This raises the question to which
extent "learning effects", "incremental innovation" (related to out-
comes), and "context-dependence of outcomes" are accounted for
in peer reviewed, full economic evaluations of medical devices.
This review aims to answer this question, discuss some policy con-
sequences of not dealing with these challenges, and through that
to raise awareness about these challenges and their handling in ap-
plied economic evaluations, and ultimately improve the quality of
economic evaluations of medical devices and decisions based upon
these. 
In this review Transcatheter Aortic Valve Implementation (TAVI)
is used as a case study. TAVI is a recently developed, minimal in-
vasive technology initially aimed at inoperable patients with symp-
tomatic aortic valve stenosis. In this context, TAVI was shown to be
cost-effective [11] . Currently, the indication of TAVI has broadened
towards patients with aortic valve stenosis (AS) who are also eli-
gible for surgical aortic valve replacement (SAVR) [11] . This review
focuses on economic evaluations of TAVI with SAVR as compara-
tor. For TAVI, as a complicated, recent and developing technique,
each of the three challenges mentioned above is potentially rele-
vant when performing an economic evaluation. Recent economic
evaluations for TAVI in this context are available, making this in-
tervention a suitable case for this study. In addition, the aforemen-
tioned, recently broadened indication of TAVI may have influenced
its costs and outcomes, making TAVI, especially compared to SAVR,
a currently relevant topic for policy makers. 
As part of the MedtecHTA project Tarricone et al. [12] previ-
ously reviewed published economic evaluations (published until
December 2014) in order to investigate how they handled four
distinctive features of medical devices, including “learning effects”
and “incremental innovation”. Based on two case studies, TAVI (for
all indications) and implantable cardioverter defibrillators (ICD), it
was concluded that general awareness of specific features of med-
ical devices is low in the context of health technology assessments
(HTA). Meanwhile, the results of the MedtecHTA project have beenPlease cite this article as: J.J. Enzing, S. Vijgen, S. Knies et al., Do eco
and context dependency? A review, Health Policy and Technology, httpublished and have informed methodological guidance for the as-
essment of medical devices issued by EUnetHTA [13] . The current
eview therefore updates the study by Tarricone et al. in the spe-
ific context of economic evaluations of TAVI with SAVR as com-
arator, enabling to assess whether the awareness about / inclu-
ion of learning effects and incremental innovation has increased
n published economic evaluations since 2015. 
ethods 
earch strategy and inclusion criteria 
The systematic review was conducted according to PRISMA
uidelines [14] . On November 12th 2018 PubMed was searched
o identify publications which fulfilled the inclusion criteria: these
ublications should contain information on costs and benefits, aor-
ic valve stenosis, transcatheter valve implantation, and surgery
see appendix I). No time restriction was applied. Subsequently,
wo reviewers (JE & SV) independently reviewed the results, ex-
luding publications which did not report full economic evalua-
ions of TAVI versus SAVR for patients with AS, based on the titles
nd abstracts of the identified publications. As a result, cost stud-
es, editorials and letters to the editor were excluded. In case of
ifferences between the reviewers, agreement was found through
iscussion between the two reviewers. Using the full articles of
he remaining publications, the two reviewers independently de-
ermined whether articles could be regarded as full economic eval-
ations of TAVI versus SAVR for patients with AS. Again, differ-
nces were resolved through discussion between the two review-
rs. Systematic reviews were excluded from this final selection,
owever, their references were cross-checked for relevant full eco-
omic evaluations. No search for grey literature was performed,
lso based on the assumption that policy makers would typically
refer to obtain evidence from peer reviewed studies in the deci-
ion making process. 
ethodological quality assessment 
To determine the quality of the included economic evalua-
ions, the extended Consensus Health Economic Criteria list (CHEC-
xtended) [15,16] was used. This tool was selected since it was de-
eloped to assess both trial based as model based full economic
valuations, both included in the review. The CHEC-extended list
as twenty questions, with response options “yes” or “no”. The
wo reviewers separately scored the included economic evaluations
sing this checklist. In case of differences in scoring, agreement
as found through discussion between the two reviewers. For each
conomic evaluation, a quality ratio was composed by relating the
umber of positive answers to the number of applicable questions.
ince the impact of the individual questions on quality may be in-
omparable, this ratio must be interpreted with care. 
ata extraction 
General study characteristics (e.g. perspective) were extracted
sing a data extraction form (JE, validated by SV). This data ex-
raction form was designed by the authors and implemented in
icrosoft Excel. Publications were read in full by the two review-
rs and for each publication text-elements (and their section titles)
ere copied to the extraction form when they were regarded to
oncern: 
• Learning effects: (potential) changes in the efficacy and/or costs
of the intervention (TAVI) related to the cumulative experience
of operators and/or centres; nomic evaluations of TAVI deal with learning effects, innovation, 
s://doi.org/10.1016/j.hlpt.2020.09.006 
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m  • Incremental innovation related to outcomes: (potential)
changes in the efficacy and/or costs of the intervention re-
lated to its (incremental) innovation through time; 
• Context-dependency of outcomes: influence of personal charac-
teristics of the care provider and/or the organisational context
(e.g. organisational size and organisational structure) on the ef-
ficacy and/or costs of the intervention. 
Based on the presence of text-elements on these methodolog-
cal challenges, these challenges were regarded as undiscussed or
iscussed within a specific publication. Additionally, the reviewers
etermined whether any of the challenges mentioned in the text
esulted in methodological choices to account for these challenges.
f this was the case, this was noted as an analytical solution in our
eview. Differences between judgements were resolved after dis-
ussion between the two reviewers. 
nalyses 
Publications before and after 2015 were compared in terms of
he number of challenges discussed per study. 
As additional information the results of the economic evalua-
ions (e.g. ICERs) were extracted, also to explore whether TAVI out-
omes improved over time, which could suggest learning effects
nd/or incremental innovation in subsequent studies. 
esults 
The literature search resulted in 207 studies, of which 15 stud-
es were finally included (see Fig. 1 ). Studies were excluded for not
eing a full economic evaluation (e.g. cost studies) (n = 147), or
ubsequently for not concerning a comparison of TAVI to SAVR for
perable AS patients. Ten systematic reviews were found and usedPlease cite this article as: J.J. Enzing, S. Vijgen, S. Knies et al., Do eco
and context dependency? A review, Health Policy and Technology, httpo check their references to find additional peer reviewed full eco-
omic evaluations. This did not result in additional studies. Note-
orthy, one included HTA-report [17] concerned an update of an-
ther included HTA-report [18] which is also described in a journal
rticle [19] . This overlap was not considered problematic, so both
ere retained. 
ethodological quality assessment 
The assessment of methodological quality of the included stud-
es using the extended CHEC-list resulted in scores ranging from
2/20 (60 percent) to 17/19 (89 percent). Ten of the checklist items
id not differentiate between studies, e.g. all clearly described their
tudy population. No study discussed each validation type required
y the checklist. Studies differed in terms of their scores regarding
ppropriateness of their costs measurement and valuation. Some
quated costs with an assumed reimbursement tariff [20] . Differ-
nces were also observed in the explicit indication of potential
onflict of interest in the published papers. Ethical and distribu-
ional issues were rarely discussed. 
tudy characteristics 
Characteristics of the fifteen included studies are provided in
able 1 . The studies were published from 2012 until 2018, most
12/15) were model based, and most used a payer’s perspective
12/15). Most studies (10/15) were North American (Canada, USA)
r European (four; United Kingdom, Belgium, Spain) and one was
apanese. Ten studies used a time horizon of ten years or more.
ost studies (10/15) were based on the industry-sponsored, multi-
entre, randomized controlled Placement of Aortic Transcatheter
alves (PARTNER) trial. Studies targeted two types of operable pa-
ients: those with high surgical risk (11/15) and those with inter-



















































































Author Country Target population Interventions Comparator Analytic approach Time horizon Efficacy source Cost source Perspective Discounting 
Reynolds et al. [21] USA high surgical risk TAVI (TF and TA) 
Edwards SAPIEN 
SAVR Trial based 1 year PARTNER A US hospital billing 





Neyt et al. [23] Belgium high surgical risk TAVI (TF and TA) 
Edwards SAPIEN 












Tuzcu, Svensson, & 
Marwick [20] 
USA high surgical risk TAVI (TF) Edwards 
SAPIEN 










Gada, Agarwal, & 
Marwick [25] 
USA high surgical risk TAVI (TA) Edwards 
SAPIEN 






Sehatzadeh et al. 
[18] 
Canada high surgical risk TAVI (TF and TA) 
Edwards SAPIEN 
SAVR Model based 20 years PARTNER Ontario Case Costing 





Doble et al. [19] Canada high surgical risk TAVI (TF and TA) 
Edwards SAPIEN 






Fairbairn et al. [26] UK high surgical risk TAVI (TF and TA) 
Edwards SAPIEN 
SAVR Model based 10 years Utility data from a UK 
high-risk AS 
population PARTNER A 
UK costs UK care 
pathway 
UK National Health 
Service 
3.5% 
Sehatzadeh et al. 
[17] 
Canada high surgical risk TAVI (TF and TA) 
Edwards SAPIEN 
SAVR not stated not stated 2-year follow-up of 
the PARTNER trial 
Ontario Case Costing 





Orlando et al. [27] UK high surgical risk TAVI Edwards 
SAPIEN 
mixture of SAVR 
(90%) and medical 
management (10%) 
Model based 25 years / lifetime PARTNER B Reference prices and 
literature 
UK National Health 
Service 
3.5% 
Ribera et al. [28] Spain intermediate 
surgical risk 
TAVI (TF) Edwards 
SAPIEN Medtronic 
CoreValve 








Reynolds et al. [22] USA high surgical risk TAVI Medtronic 
CoreValve 
SAVR Trial based lifetime CoreValve U.S. High 
Risk Pivotal Trial 
CoreValve U.S. High 
Risk Pivotal Trial 
(resource utilization, 






Canada high surgical risk TAVI Medtronic 
Corevalve 
SAVR Model based 5 years U.S. CoreValve Pivotal 
Trial 





Kodera et al. [30] Japan intermediate 
surgical risk 
TAVI (TF) Edwards 
Sapien XT 
SAVR Model based 10 years PARTNER 2 cohory A 
Optimizes Catheter 
vAlvular iNtervention 
(OCEAN) TAVI registry 









TAVI (TF and TA) 
Edwards Sapien XT 
SAVR Model based lifetime PARTNER 2 cohory A 
Optimizes Catheter 
vAlvular iNtervention 
(OCEAN) TAVI registry 
Canadian Institue of 
Health Information, 
Ontario Schedule of 










TAVI (TF and 
non-TF) Medtronic 
CoreValve 
Medtronic Evolut R 
SAVR Model based lifetime SURTAVI trial / 
CoreValve US High 
Risk Pivotal Trial 
(EQ-5D) 
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r f Edwards LifeSciences (11/15), others investigated a TAVI valve
ystem of Medtronic, Inc. (3/15), and one study investigated sys-
ems of both manufacturers. One of the studies was limited to
ransapical (TA) implantation of TAVI, the other studies investi-
ated (the less-invasive) transfemoral (TF) implantation or a com-
ination of both routes. 
ost-effectiveness results 
Cost-effectiveness outcomes as reported in the included stud-
es are provided in Table 2 . All studies reported incremental ef-
ects measured in QALY’s, while one-third (5/15) also reported in-
remental effects measured in life-years-gained. The reported in-
remental effect of TAVI in QALY’s was mostly positive (9/15), and
ost studies reported additional costs (12/15). All studies pre-
ented a sensitivity analysis to quantify uncertainties. Five studies
eported that TAVI was dominated by SAVR, two studies reported
AVR was dominated by TAVI, the other studies reported TAVI to
ave an incremental cost-effectiveness ratio (ICER) ranging from
expressed in euros) €31,0 0 0 to €750,0 0 0 per QALY. The variation
n the extracted cost-effectiveness results may partly be explained
y observed differences in study characteristics, among which
ountry, perspective and the cost and efficacy sources used were
rominent ones. Furthermore, the reported incremental QALY’s ap-
eared to have an upward trend over time. All studies included
ome form of sensitivity analysis, among which one-way determin-
stic sensitivity analysis and probabilistic sensitivity analysis were
he most common types of sensitivity analysis (in eleven and ten
tudies, respectively). None of the sensitivity analysis attempted to
uantify the potential impact of learning effects or incremental in-
ovation on the ICER. One of the analyses demonstrated the po-
ential impact of context on cost-effectiveness by imputing coun-
ry specific costs in two scenarios, changing the reported ICER from
ominated in the base case to dominant in (some of) these scenar-
os [28] . 
ethodological challenges 
Table 3 provides the results of the review per study. This ta-
le shows that each of the three methodological challenges was
iscussed in one or more of the studies. Two studies discussed
ll three challenges [21,22] , while four studies discussed none
16,18,23,24] . The two studies which discussed all three were
mong the studies with the highest CHEC-list scores. Studies which
iscussed no or one challenge had a mean CHEC-score of 76%,
tudies which discussed two or three challenges had a mean CHEC-
core of 85%, suggesting a potential relationship between number
f discussed challenges and assessed methodological quality. Ob-
iously, sample size prohibits formal testing or firm conclusions.
hallenges were discussed in the “Discussion” (or “Comment”) sec-
ions of the studies or, in one study, in the “Introduction” [27] .
wo studies used ‘analytical solutions’ to deal with identified chal-
enges. The first study was restrictive in the selection of registry
ata. It selected those registries that allowed inclusion of data af-
er an initial learning effect, hence avoiding data from situations
n which proper training and experience was not yet realized. This
as highlighted in the “Discussion” section [25] of the publication.
he second study concerned additional analyses to deal with (high-
evel) context dependency, i.e. an international comparison of re-
ults, by using information (i.e. imputing unit costs) from other
ountries and health care systems to understand cost-effectiveness
n these contexts, rather than the country of origin. This issue was
escribed in the “Methods” section [28] of the study. The results
ighlighted that cost-effectiveness estimates were quite sensitive
o these country specific unit cost parameters. Please cite this article as: J.J. Enzing, S. Vijgen, S. Knies et al., Do economic evaluations of TAVI deal with learning effects, innovation, 
and context dependency? A review, Health Policy and Technology, https://doi.org/10.1016/j.hlpt.2020.09.006 
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Table 3 
Discussed challenges (1 = discussed, 0 = undiscussed). 
Author Learning effects (discussed) Incremental innovation (discussed) Context dependence of results (discussed) 
Reynolds et al. [21] 1 1 1 
Neyt et al. [23] 0 0 0 
Gada, Kapadia, et al. [20] 0 1 0 
Gada, Agarwal, & Marwick [25] 1 0 0 
Sehatzadeh et al. [18] 0 0 0 
Doble et al. [19] 0 1 1 
Fairbairn et al. [26] 0 0 1 
Sehatzadeh et al. [17] 0 0 0 
Orlando et al. [27] 1 0 0 
Ribera et al. [28] 0 0 1 
Reynolds et al. [22] 1 1 1 
Health Quality Ontario [29] 1 1 0 
Kodera, Kiyosue, Ando, & Komuro [30] 0 1 1 
Tam, Hughes, Fremes, et al. [24] 0 0 0 
Tam, Hughes, Wijeysundera, & Fremes [31] 0 1 1 


















































































r  Learning effects 
Five studies discussed learning effects, three of which labelling
it as “learning curves” or “learning curve effects”. For example,
Reynolds [21] wrote that “most PARTNER sites did not perform
enough TA-TAVR procedures to move beyond the point of learning
curve effects ”. The remaining two studies described a positive re-
lation between experience and outcomes. For example, “In centres
experienced in conducting TAVIs, procedural success may be around
90% or more and closely linked to experience, with greater learn-
ing resulting in better patient selection and outcomes " [27] . One of
the five studies described how learning effects were taken into ac-
count in its model-based analysis: “Given the recent development of
transapical TAVI, we did not include data from registries emphasiz-
ing results of a ‘learning curve’. Only registries that separated recent
procedures, once proper proctoring and training had been completed,
were included in the data employed in the model ” [25] . 
Incremental innovation 
In seven of the included studies potential developments of TAVI
or its comparator were explicitly related to (future) outcomes,
costs and/or the ICER. For example, “It is reasonable to expect that
iterative improvements in TAVR technology in the short to intermedi-
ate term, coupled with increased clinical experience, will lead to re-
duced complication rates, more efficient care, reduced costs, and im-
proved cost-effectiveness relative to SAVR, a much more mature ther-
apy. ” [22] . No methodological solutions to cope with incremental
innovation (e.g. specific sensitivity analysis) were found in the ar-
ticles. 
Besides these seven studies, three other studies contained a text
fragment that implied that innovation of the intervention is con-
tinuing in daily practice, although without explicitly relating this
phenomenon to (future) outcomes, costs and/or the ICER. As exam-
ples, Gada et al. labelled TAVI as “a developing technique ” [25] and
Orlando et al. stated that “more sophisticated delivery systems have
been developed. ” [27] . 
Context dependent outcomes 
Seven studies discussed that their results may not be generaliz-
able to other contexts 
(e.g. jurisdictions or treatment settings). One study [28] con-
ducted a scenario analysis to demonstrate results for additional
countries by imputing observed unit costs, as highlighted above.
Four of the seven studies specifically discussed the context of care
provision (e.g. the specific hospital). For example, “We recognize
that there is substantial institutional heterogeneity with respect to
procedural location and resources, and this factor may potentially af-
fect the ICER. ” [31] . Please cite this article as: J.J. Enzing, S. Vijgen, S. Knies et al., Do eco
and context dependency? A review, Health Policy and Technology, httpTo assess in a general fashion whether the awareness, measured
s being discussed, of the three challenges increased since the end
f 2015, we compared publications before and after 2015 in terms
f the number of challenges discussed per study. Ten studies were
ublished in 2015 or before. In these ten studies on average one
hallenge was discussed (see Table 3 ). Five studies were published
fter 2015. These studies on average discussed 1.8 challenges (i.e.
ine in total). Notwithstanding the low numbers and rough indica-
or, this may suggest at least an increase in awareness of the chal-
enges related to the economic evaluation of TAVI. Whether this
ncreased awareness is representative for other medical devices, or
.g. results from the elapsed time since the introduction of TAVI
time effect) requires further research. 
iscussion 
This paper reviewed the extent to which three methodological
hallenges of particular importance to medical devices, were dis-
ussed in peer reviewed full economic evaluations of TAVI, and
hether analytical solutions were provided. It was observed that
hese challenges and their influence on the validity of reported re-
ults of economic evaluations, are typically only partly discussed
nd rarely quantitatively dealt with in the reviewed economic eval-
ations of TAVI. This seems inappropriate from a general HTA per-
pective. Within an HTA process, economic evaluations are part of
he information which is systematically collected and synthesized
uring the assessment, to inform a subsequent appraisal phase.
uring the latter, the available evidence is critically appraised in
erms of validity, significance and relevance, along with known un-
ertainties and all societal and ethical considerations deemed rele-
ant. Information on methodological challenges, both resolved and
nresolved, is needed to inform these deliberations. It seems this
nformation is mostly lacking in reports on economic evaluations
f TAVI. 
For each of the three challenges, this observed absence of in-
ormation may have specific consequences for policy makers. First,
nly one study explicitly corrected for the influence of accumu-
ated experience on outcomes. However, the literature highlights
hat significant learning effects exist in TAVI care provision, both
ffectiveness as costs are influenced by experience [32–35] . Conse-
uently, when care providers’ experience levels within trials used
n economic evaluation differ from those in current or expected
ractice, the reported ICERs may not reflect actual clinical prac-
ice. For example, ICERs, which may aim to represent long-term
ost-effectiveness of the use of an intervention, may be overesti-
ated when short-term trial results are extrapolated without cor-
ecting for short-term inefficiencies such as learning effects [36] .nomic evaluations of TAVI deal with learning effects, innovation, 
s://doi.org/10.1016/j.hlpt.2020.09.006 
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s  iven that readily available techniques to deal with these issues
re lacking, one may argue that it cannot be expected from ap-
lied economic evaluations that they deal with or correct for this
ssue in a quantitative fashion. However, the relevance of (the po-
ential influence of on outcomes of) learning effects also mostly
emained undiscussed, which could result in unawareness about
hese issues among policy makers, and lead to an overestimation
f the validity of the reported ICER by them. As an illustration of
he potential impact of this issue, a combination of strong confi-
ence with an overestimated ICER may result in rejecting an inter-
ention that might be cost-effective in the longer run. Moreover,
iscussing the potential discrepancy between short-term and long-
erm efficiency may also avoid disappointment with short-term re-
ults after implementation of the intervention [37] . Second, none
f the studies provided or applied an explicit analytical solution to
ope with incremental innovation which may influence outcomes,
nd numerous studies did not discuss this aspect. However, multi-
le innovations which influenced TAVI outcomes have occurred, for
xamples new generations of valves and new strategies for proce-
ure optimization were introduced [38,39] . Furthermore, new in-
ovations, including those concerning alternative access routes, are
xpected. Such incremental innovations may be relevant for pol-
cy makers. As an illustration, one could consider the extremely
ivergent cost-effectiveness outcomes of the transfemoral (domi-
ant) and the transapical access route (dominated) reported within
 single study [21] . As a consequence of incremental innovation,
eported ICERs may be especially relevant in the short-term. This
spect often is not mentioned explicitly, and remained undiscussed
n almost half of the studies. It is clear that one should try to avoid
valuations reporting on already obsolete technologies or applica-
ion procedures to inform reimbursement decisions that do not
ertain (only) to the studied interventions but also those currently
n place. Policy makers therefore need to be aware of this, to avoid
uboptimal reimbursement decisions. Awareness of incremental in-
ovation may lead policy makers to apply a more adaptive ap-
roach to health technology assessment [40] which may help in
ealing with this challenge. Third, except for one of the reviewed
tudies (which highlighted a scenario analysis for other countries)
28] none of the studies provided or used an analytical solution
pproach to cope with the dependence of outcomes on the con-
ext of care provision, and most did not discuss this dependency.
onetheless, context dependency of outcomes is of relevance for
AVI; e.g. hospitals differ in their mix of access routes, in devices
sed, and in operation settings [41] , which are elements affecting
he ‘local ICER’. For example, Ribera et al. presented ICERs for both
ajor valve manufacturers (Edwards Lifesciences and Medtronic)
eparately, suggesting differences between these ICERs [28] . It can
e argued that the challenge of context dependency has been mit-
gated to a certain extent by using parameters from the PARTNER
rial as these are based on multiple centres. However, although
ARTNER was a multicentre RCT, it was limited to valves of Ed-
ards Lifesciences. Moreover, reported average ICERs may still not
e valid for all contexts and in centres with other characteristics
han the included ones. This limitation mostly remained undis-
ussed, potentially leaving policy makers unaware of risks in gen-
ralising the results of the studies to the context of the relevant
olicy question at hand. However, the potential policy relevance of
his issue may be illustrated by considering the different scenario’s
eported by Ribera et al. [28] , ranging from dominated (a policy ar-
ument to reject reimbursement) to dominant (a policy argument
o allow reimbursement). 
Taken together, the distinctive features of medical devices result
n methodological challenges which were typically not accounted
or in economic evaluations of TAVI. As a result, dealing with these
hallenges is, mostly implicitly, passed on to policy makers. When
olicy makers are unaware of these challenges, they may overesti-Please cite this article as: J.J. Enzing, S. Vijgen, S. Knies et al., Do eco
and context dependency? A review, Health Policy and Technology, httpate the relevance of reported cost-effectiveness results for their
ecision context. This could result in non-optimal decisions regard-
ng funding these technologies or to a lack of additional informa-
ion gathering to come to more relevant and up-to-date estimates
f cost-effectiveness. 
It could be suggested that the three methodological challenges
ere omitted in the included economic evaluations because of a
resumed small impact on the ICER. However, this would require a
uantification of their impact which was not provided within these
valuations. Also, some of the examples above suggest that their
nfluence can indeed be substantial. 
Exploring the impact on ICERs of dealing with (any of) the three
hallenges is hampered by the fact that only one study reported
andling learning effects [25] . This study reported an incremen-
al effect (-0.04 QALY) slightly below the average (0.02 QALY) but
alling well within the range of incremental effects (-0.61 QALY to
.23 QALY) reported in the included studies. The incremental costs
eported in this study also fell within the range of reported values.
It should be noted that it may be unreasonable to expect
ndividual economic evaluations to find and use technical solu-
ions for the fundamental and complicated challenges highlighted
ere, without clear guidance how to do so. Although ready to use
echnical solutions may not be available, in current international
ethodological guidance on the assessment of medical devices
e,g. [13] ) and in national HTA guidelines (e.g. England, France, the
etherlands, and Sweden) [42] the specific methodological chal-
enges are extensively acknowledged. Consequently, it could be
easonably expected that studies would at least mention these
hallenges and particularly their potential impact on the results,
lso to inform policy makers who may use the results of studies.
eporting study details on the level of operators’ experience, or-
anisational context and interventions, would allow policy makers
o judge their similarity with health provision in their own context.
While our results suggest some improvement over time, they
lso show that still not all current studies mention these chal-
enges and their potential impact. To stimulate further improve-
ent, policy makers could enforce submitters of economic evalu-
tions to specify how they handled specific methodological chal-
enges of the intervention concerned. Moreover, future research
ould contribute to the further development of methodology deal-
ng with these challenges, and the development of best practices
o illustrate how to do so in economic evaluations. 
As mentioned, the consideration of learning effects and incre-
ental innovation in economic evaluations of TAVI has been sub-
ect of previous research. Tarricone and colleagues [12] showed in
heir review among other results that a minority of HTA-reports
nd journal articles on TAVI considered “learning curves” (42 per-
ent of included publications) and “incremental innovation” (37
ercent of included publications). Our results were in line with
heir results, showing moderate improvement over time in terms
f the consideration of these challenges. Based on their results,
ombined with comparable results for economic evaluations of im-
lantable cardioverter defibrillators (ICD), they concluded that the
eneral awareness of specific features of medical devices is low in
he context of economic evaluation. Our review confirms their con-
lusion, despite the developments in this field since their study, in-
luding the publication of specific guidance. Hence, more effort is
eeded to increase the awareness about these challenges, their ex-
licit mentioning in economic evaluations, and the availability of
ethodological techniques to deal with these issues. 
As an additional observation, acknowledging the low number
f included studies, an upward trend appears to be observed over
ime, in terms of the reported incremental QALY’s gained. This po-
ential trend may suggest a relative improvement of TAVIs effec-
iveness over time. However, it needs to be noted that the fifteen
tudies included in our review differed in terms of the risk class ofnomic evaluations of TAVI deal with learning effects, innovation, 
s://doi.org/10.1016/j.hlpt.2020.09.006 
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their target population as well as the applied time horizon (rang-
ing from 1 year to lifetime). Such differences warrant caution in
the interpretation of these effectiveness results. 
Limitations of this review 
A number of limitations of this review deserve mentioning.
First, this review only dealt with one particular medical device:
TAVI. Hence, generalisations to other medical devices cannot be
made, especially since medical devices consist of a large and het-
erogeneous collection of technologies [43] . For example, while TAVI
is an artificial body part implanted by a medical procedure, other
devices may concern assistive devices directly used by patients. In
the latter category, in contrast to TAVI, a learning curve on patient
side may be expected. For diagnostic technologies other method-
ological challenges may apply compared to therapeutic technolo-
gies like TAVI. Finally, for pragmatic reasons the search for this
study was limited to one digital database (Pubmed) although sev-
eral other digital databases (e.g. Embase, Web of Science) are avail-
able. However, given that the identified systematic reviews and the
study of Tarricone et al. did not include peer reviewed studies that
did not show up in our results, this suggests our search strategy
was quite adequate in retrieving relevant studies. 
Conclusion 
The challenges related to economic evaluations of medical
devices and their influence on the validity of reported cost-
effectiveness results, are typically discussed incompletely and
rarely dealt with in peer reviewed studies on TAVI. It is important
for research and policy that this improves. Best practices should
be developed to support the application of technical solutions, and
policy makers should require submitters to at least reflect on spe-
cific methodological challenges of the intervention concerned. 
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